Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Impact of genetic variation in CYP2C19, CYP2D6, and CYP3A4 on oxycodone and its metabolites in a large database of clinical urine drug tests

The Pharmacogenomics Journal volume 22, pages 25–32 (2022)Cite this article

Subjects

Abstract

Urine drug testing (UDT) is a tool for monitoring drug use, including oxycodone. While variation in cytochrome P450 (CYP) genes is known to alter oxycodone metabolism, its impact on UDT results of oxycodone and its metabolites has not been well-studied. Here, multivariate analysis was performed on retrospective UDT results of 90,379 specimens collected from 14,684 genotyped patients prescribed oxycodone. Genetic variation in CYP2D6 and CYP2C19 had a significant impact on oxymorphone/oxycodone ratios, with a 6.9-fold difference between CYP2D6 ultrarapid metabolizers (UMs) and poor metabolizers (PMs; p < 10−300) and a 1.6-fold difference between CYP2C19 UMs and PMs (p = 1.50 × 10−4). CYP2D6 variation also significantly impacted noroxycodone/oxycodone ratios (p = 6.95 × 10−38). Oxycodone-positive specimens from CYP2D6 PMs were ~5-fold more likely to be oxymorphone-negative compared to normal metabolizers. These findings indicate that multivariate analysis of UDT data may be used to reveal the real-world impact of genetic and non-genetic factors on drug metabolism.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Selection of patients and urine specimens for data analysis.
Fig. 2: Urinary oxymorphone/oxycodone (A) and noroxycodone/oxycodone (B) metabolic ratios by CYP2C19, CYP2D6, and CYP3A4 phenotypes.
Fig. 3: Marginal least square (LS) mean estimates of oxymorphone/oxycodone metabolic ratios for CYP2D6 (A) and CYP2C19 (B) phenotypes.
Fig. 4: Marginal least square (LS) mean estimates of noroxycodone/oxycodone metabolic ratios for CYP2D6 (A) and CYP3A4 (B) phenotypes.

Similar content being viewed by others

Data availability

The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request.

References

  1. Jarvis M, Williams J, Hurford M, Lindsay D, Lincoln P, Giles L, et al. Appropriate use of drug testing in clinical addiction medicine. J Addict Med. 2017;11:163–173.

    Article  Google Scholar 

  2. US Drug Enforcement Administration, Diversion Control Division, Drug & Chemical Evaluation Section. Oxycodone. https://www.deadiversion.usdoj.gov/drug_chem_info/oxycodone/oxycodone.pdf. Revised March 2020. Accessed 12 Nov 2020.

  3. Kinnunen M, Piirainen P, Kokki H, Lammi P, Kokki M. Updated clinical pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacokinet. 2019;58:705–25.

    Article  CAS  Google Scholar 

  4. Huddart R, Clarke M, Altman RB, Klein TE. PharmGKB summary: oxycodone pathway, pharmacokinetics. Pharmacogenet Genomics 2018;28:230–7.

    Article  CAS  Google Scholar 

  5. Elder NM, Atayee RS, Best BM, Ma JD. Observations of urinary oxycodone and metabolite distributions in pain patients. J Anal Toxicol. 2014;38:129–34.

    Article  CAS  Google Scholar 

  6. Lalovic B, Kharasch E, Hoffer C, Risler L, Liu-Chen LY, Shen DD. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharm Ther. 2006;79:461–79.

    Article  CAS  Google Scholar 

  7. Moy KV, Ma JD, Morello CM, Atayee RS, Best BM. Monitoring oxycodone use in patients with chronic pain: analysis of oxycodone and metabolite excretion in saliva and urine. J Opioid Manag. 2014;10:47–56.

    Article  Google Scholar 

  8. Yee DA, Best BM, Atayee RS, Pesce AJ. Observations on the urine metabolic ratio of oxymorphone to oxycodone in pain patients. J Anal Toxicol. 2012;36:232–8.

    Article  CAS  Google Scholar 

  9. Cone EJ, Heltsley R, Black DL, Mitchell JM, Lodico CP, Flegel RR. Prescription opioids. I. Metabolism and excretion patterns of oxycodone in urine following controlled single dose administration. J Anal Toxicol. 2013;37:255–64.

    Article  CAS  Google Scholar 

  10. Substance Abuse and Mental Health Services Administration. Clinical drug testing in primary care. Technical Assistance Publication (TAP) 32. HHS Publication No. (SMA) 12-4668. Substance Abuse and Mental Health Services Administration: Rockville, MD, USA, 2012.

  11. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). https://drug-interactions.medicine.iu.edu/MainTable.aspx. Accessed 12 Nov 2020.

  12. Desta Z, Gammal RS, Gong L, Whirl-Carrillo M, Gaur AH, Sukasem C, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2B6 and efavirenz-containing antiretroviral therapy. Clin Pharm Ther. 2019;106:726–33.

    Article  Google Scholar 

  13. Pratt VM, Cavallari LH, Del Tredici AL, Hachad H, Ji Y, Moyer AM, et al. Recommendations for clinical CYP2C9 genotyping allele selection: a joint recommendation of the Association for Molecular Pathology and College of American Pathologists. J Mol Diagn. 2019;21:746–55.

    Article  CAS  Google Scholar 

  14. Pratt VM, Del Tredici AL, Hachad H, Ji Y, Kalman LV, Scott SA, et al. Recommendations for clinical CYP2C19 genotyping allele selection: a report of the Association for Molecular Pathology. J Mol Diagn. 2018;20:269–76.

    Article  CAS  Google Scholar 

  15. Caudle KE, Rettie AE, Whirl-Carrillo M, Smith LH, Mintzer S, Lee MT, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. Clin Pharm Ther. 2014;96:542–8.

    Article  CAS  Google Scholar 

  16. Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharm Ther. 2013;94:317–23.

    Article  CAS  Google Scholar 

  17. Del Tredici AL, Malhotra A, Dedek M, Espin F, Roach D, Zhu GD, et al. Frequency of CYP2D6 alleles including structural variants in the United States. Front Pharmacol. 2018;9:305.

    Article  Google Scholar 

  18. PharmGKB. Frequencies of CYP2C9 alleles in biogeographical groups. https://api.pharmgkb.org/v1/download/file/attachment/CYP2C9_frequency_table.xlsx. Accessed 12 Nov 2020.

  19. Birdwell KA, Decker B, Barbarino JM, Peterson JF, Stein CM, Sadee W, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. Clin Pharm Ther. 2015;98:19–24.

    Article  CAS  Google Scholar 

  20. Crews KR, Monte AA, Huddart R, Caudle KE, Kharasch ED, Gaedigk A, et al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6, OPRM1, and COMT genotypes and select opioid therapy. Clin Pharmacol Ther. 2021.

  21. Sanchez Spitman AB, Moes D, Gelderblom H, Dezentje VO, Swen JJ, Guchelaar HJ. Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism. Eur J Clin Pharmacol. 2017;73:1589–98.

    Article  CAS  Google Scholar 

  22. Zanger UM, Klein K. Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance. Front Genet. 2013;4:24.

    Article  CAS  Google Scholar 

  23. Andreassen TN, Eftedal I, Klepstad P, Davies A, Bjordal K, Lundstrom S, et al. Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study. Eur J Clin Pharmacol. 2012;68:55–64.

    Article  CAS  Google Scholar 

  24. Liukas A, Kuusniemi K, Aantaa R, Virolainen P, Neuvonen M, Neuvonen PJ, et al. Plasma concentrations of oral oxycodone are greatly increased in the elderly. Clin Pharm Ther. 2008;84:462–7.

    Article  CAS  Google Scholar 

  25. Naito T, Takashina Y, Yamamoto K, Tashiro M, Ohnishi K, Kagawa Y, et al. CYP3A5*3 affects plasma disposition of noroxycodone and dose escalation in cancer patients receiving oxycodone. J Clin Pharmacol. 2011;51:1529–38.

    Article  CAS  Google Scholar 

  26. Samer CF, Daali Y, Wagner M, Hopfgartner G, Eap CB, Rebsamen MC, et al. The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. Br J Pharmacol. 2010;160:907–18.

    Article  CAS  Google Scholar 

  27. Stamer UM, Zhang L, Book M, Lehmann LE, Stuber F, Musshoff F. CYP2D6 genotype dependent oxycodone metabolism in postoperative patients. PLoS ONE 2013;8:e60239.

    Article  CAS  Google Scholar 

  28. Zwisler ST, Enggaard TP, Noehr-Jensen L, Pedersen RS, Mikkelsen S, Nielsen F, et al. The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism. Basic Clin Pharm Toxicol. 2009;104:335–44.

    Article  CAS  Google Scholar 

  29. Lalovic B, Phillips B, Risler LL, Howald W, Shen DD. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos. 2004;32:447–54.

    Article  CAS  Google Scholar 

  30. Gronlund J, Saari TI, Hagelberg NM, Neuvonen PJ, Laine K, Olkkola KT. Effect of inhibition of cytochrome P450 enzymes 2D6 and 3A4 on the pharmacokinetics of intravenous oxycodone: a randomized, three-phase, crossover, placebo-controlled study. Clin Drug Investig. 2011;31:143–53.

    Article  CAS  Google Scholar 

  31. Gronlund J, Saari TI, Hagelberg NM, Neuvonen PJ, Olkkola KT, Laine K. Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone. Br J Clin Pharmacol. 2010;70:78–87.

    Article  CAS  Google Scholar 

  32. Heiskanen T, Olkkola KT, Kalso E. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharm Ther. 1998;64:603–11.

    Article  CAS  Google Scholar 

  33. Lemberg KK, Heiskanen TE, Neuvonen M, Kontinen VK, Neuvonen PJ, Dahl ML, et al. Does co-administration of paroxetine change oxycodone analgesia: an interaction study in chronic pain patients. Scand J Pain. 2010;1:24–33.

    Article  CAS  Google Scholar 

  34. Klein K, Zanger UM. Pharmacogenomics of cytochrome P450 3A4: recent progress toward the “missing heritability” problem. Front Genet. 2013;4:12.

    Article  CAS  Google Scholar 

  35. Jannetto PJ, Bratanow NC, Clark WA, Hamill-Ruth RJ, Hammett-Stabler CA, Huestis MA, et al. Executive summary: American Association of Clinical Chemistry Laboratory Medicine Practice Guideline—Using clinical laboratory tests to monitor drug therapy in pain management patients. J Appl Lab Med. 2018;2:489–526.

    Article  Google Scholar 

  36. Raouf M, Bettinger JJ, Fudin J. A practical guide to urine drug monitoring. Fed Pract. 2018;35:38–44.

    PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors thank Karthika Balasubramanian for critical review of the study design and results.

Author information

Authors and Affiliations

  1. Millennium Health, LLC, San Diego, CA, USA

    Guang-dan Zhu, Penn Whitley, Leah LaRue, Brandon Adkins, Eric Dawson, Angela Huskey & Andria L. Del Tredici

  2. Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, USA

    Edmund V. Capparelli

  3. Department of Pediatrics, School of Medicine, University of California San Diego, La Jolla, CA, USA

    Edmund V. Capparelli

Authors
  1. Guang-dan Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Penn Whitley
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Leah LaRue
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Brandon Adkins
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Eric Dawson
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Angela Huskey
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Edmund V. Capparelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Andria L. Del Tredici
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

GZ, PW and AD conceptualized and designed the study including methodology. AH provided supervision and resources. GZ and PW performed data analysis. All authors contributed to interpretation of the results. GZ and AD took the lead on writing the paper. PW, LL, BA, ED and EC made substantial edits to the paper. All authors reviewed and approved the paper.

Corresponding author

Correspondence to Guang-dan Zhu.

Ethics declarations

Competing interests

All authors except EC were employed by Millennium Health on a full-time basis at the time this study was completed. EC declares no competing financial interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhu, Gd., Whitley, P., LaRue, L. et al. Impact of genetic variation in CYP2C19, CYP2D6, and CYP3A4 on oxycodone and its metabolites in a large database of clinical urine drug tests. Pharmacogenomics J 22, 25–32 (2022). https://doi.org/10.1038/s41397-021-00253-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41397-021-00253-5

Search

Advanced search

Quick links